Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ARGX save search
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Published: 2024-04-16 (Crawled : 05:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -5.0%
H: 4.19%
C: 2.86%
disease vyvgart for
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
Published: 2024-03-27 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.41%
H: 0.18%
C: -0.15%
disease
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
Published: 2024-03-26 (Crawled : 20:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.41%
H: 0.18%
C: -0.15%
meeting
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
Published: 2024-03-26 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.07%
H: 0.79%
C: -0.29%
japan vyvgart approval
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -0.31%
H: 1.31%
C: 0.08%
autoimmunity meeting promise
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
Published: 2024-02-29 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -3.06%
H: 0.31%
C: -1.44%
business year update financial results
argenx to Present at Upcoming Investor Conferences
Published: 2024-02-26 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.28%
H: 0.47%
C: -0.08%
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
Published: 2024-02-22 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -0.2%
H: 2.75%
C: 1.71%
report business year update financial results
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Published: 2024-02-20 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 3.75%
H: 0.26%
C: -2.84%
fda vyvgart license review application
Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published: 2024-02-12 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 3.52%
H: 0.0%
C: -1.18%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 0.06%
H: 2.34%
C: 2.29%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.14%
H: 0.35%
C: 0.07%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.34%
H: 0.23%
C: -1.13%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 1.22%
H: 0.07%
C: -0.43%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.96%
H: 1.75%
C: 1.75%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
ZLAB | $15.66 3.57% 3.45% 430K
|
Health Technology
|
| O: -1.15%
H: 1.03%
C: -1.5%
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: -0.28%
H: 0.49%
C: -0.32%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
IPHA | $2.47 4.22% 4.05% 690
|
Health Technology
|
| O: -3.1%
H: 1.2%
C: -0.8%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 3.8%
H: 1.1%
C: -1.17%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -3.72%
H: 0.58%
C: -3.82%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.26%
H: 0.73%
C: -0.36%
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -2.3%
H: 1.65%
C: 0.83%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.06%
H: 0.31%
C: -1.4%
expansion growth market
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
Published: 2024-01-18 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -0.63%
H: 0.17%
C: -1.16%
vyvdura japan approval injection
argenx Highlights 2024 Strategic Priorities
Published: 2024-01-08 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.07%
H: 5.14%
C: 4.23%
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -0.74%
H: 1.36%
C: 0.9%
conference
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
Published: 2023-12-20 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -23.64%
H: 0.34%
C: -1.94%
topline results study
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
Published: 2023-11-28 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -8.82%
H: 0.4%
C: -1.49%
vyvgart topline results study
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
Published: 2023-11-16 (Crawled : 12:30) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.0%
H: 0.34%
C: -0.36%
vyvgart approval
argenx to Present at Upcoming November 2023 Investor Conferences
Published: 2023-11-01 (Crawled : 08:00) - biospace.com/
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.8%
H: 4.96%
C: 4.53%
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
Published: 2023-11-01 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.8%
H: 4.96%
C: 4.53%
disease vyvgart sessions
argenx to Present at Upcoming Investor Conferences
Published: 2023-11-01 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.8%
H: 4.96%
C: 4.53%
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-10-31 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 2.8%
H: 0.48%
C: -1.59%
business update financial results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.